BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 first quarter, which ended December 31, 2025.

Revenue of $5.3 billion increased 1.6% as reported, 0.4% FXN New BD revenue increased 2.5% FXN GAAP and adjusted diluted EPS of $1.34 and $2.91, respectively Combination of BD's Biosciences and ...

Amount reflects the estimated impact to adjusted diluted earnings per share for fiscal year 2025 from the proposed disposition of the Bioscience and Diagnostics Solutions business that will be ...

Epic has once again been named the top Overall Health System Suite, according to the 2026 annual Best in KLAS report published this week, followed again by Meditech and Oracle Health, for the 16th ...

Jesse Jackson, who died Tuesday aged 84, had a three-pronged career of civil rights, liberal missions and political activism, and his White House bids in the 1980s helped lay the groundwork for the ...